Active Biotech: Interim Phase Ib Results from NeoTX

Research Note



NeoTX, the partner of Active Biotech developing naptumomab estafenatox, has presented new results from the phase I/IIa trial combining naptumomab with durvalumab at the AACR Annual Meeting 2023.


Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.